Literature DB >> 14604448

Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline.

Peter R Joyce1, Roger T Mulder, Suzanne E Luty, Janice M McKenzie, Allison L Miller, Geraldine R Rogers, Martin A Kennedy.   

Abstract

In 169 depressed patients randomized to treatment with either fluoxetine or nortriptyline, we examined whether polymorphisms of the serotonin transporter and the G protein beta3 subunit influenced response to these antidepressants. For depressed patients under the age of 25 yr the T allele of the G protein beta3 subunit was associated with a markedly poorer response to nortriptyline, while serotonin transporter polymorphisms did not predict antidepressant response. However, in patients 25 yr or older, the G protein beta3 polymorphisms did not predict antidepressant response, while the s,s genotype of the serotonin transporter was associated with a poorer response to both fluoxetine and nortriptyline. These differential pharmacogenetic predictors of antidepressant response by age, may provide clues to understanding the discontinuities in pharmacological responsiveness of child/adolescent and adult depressive disorders.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14604448     DOI: 10.1017/S1461145703003663

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  23 in total

Review 1.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

Review 2.  Pharmacogenomics of suicidal events.

Authors:  David Brent; Nadine Melhem; Gustavo Turecki
Journal:  Pharmacogenomics       Date:  2010-06       Impact factor: 2.533

3.  Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?

Authors:  Ari Illi; Outi Poutanen; Eija Setälä-Soikkeli; Olli Kampman; Merja Viikki; Heini Huhtala; Nina Mononen; Susann Haraldsson; Pasi A Koivisto; Esa Leinonen; Terho Lehtimäki
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-07-17       Impact factor: 5.270

Review 4.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 5.  Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.

Authors:  Tristram A Lett; Henrik Walter; Eva J Brandl
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

6.  Interaction between TPH1 and GNB3 genotypes and electroconvulsive therapy in major depression.

Authors:  S Anttila; K Huuhka; M Huuhka; R Rontu; K M Mattila; E Leinonen; T Lehtimäki
Journal:  J Neural Transm (Vienna)       Date:  2006-10-27       Impact factor: 3.575

Review 7.  Antidepressant response and the serotonin transporter gene-linked polymorphic region.

Authors:  Matthew J Taylor; Srijan Sen; Zubin Bhagwagar
Journal:  Biol Psychiatry       Date:  2010-07-07       Impact factor: 13.382

8.  Response to sertraline is influenced by GNβ3 gene G-350A variant in patients with major depressive disorder.

Authors:  Dena Firouzabadi; Negar Firouzabadi; Kiana Kalani; Kamyar Zomorrodian; Elham Shirazi Tehrani
Journal:  Eur J Clin Pharmacol       Date:  2018-10-15       Impact factor: 2.953

9.  Clinically relevant pharmacogenomic testing in pediatric practice.

Authors:  Lindsey Korbel; Mathew George; Joseph Kitzmiller
Journal:  Clin Pediatr (Phila)       Date:  2014-05-06       Impact factor: 1.168

Review 10.  How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems.

Authors:  Dennis L Murphy; Meredith A Fox; Kiara R Timpano; Pablo R Moya; Renee Ren-Patterson; Anne M Andrews; Andrew Holmes; Klaus-Peter Lesch; Jens R Wendland
Journal:  Neuropharmacology       Date:  2008-09-11       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.